Summary
Next Science Ltd (Next Science) is a medical technology company that develops and commercializes non-toxic technology products for antimicrobial resistance and bacterial biofilms. Its products include SurgX, an innovative surgical gel designed to reduce superficial surgical site infections (SSIs) and protect wound tissue that facilitates natural healing; and BlastX, an antimicrobial wound gel that destroys bacteria. Next Science's proprietary Xbio technology is non-toxic and eradicates biofilm-based and free-floating bacteria and reduces the impact of biofilm-based infections in human health. The company has patented applications across multiple market segments, including over-the-counter medications, prescription pharmaceuticals, medical devices and hospital infection control. It operates through its subsidiaries in Australia and the US. Next Science is headquartered in Chatswood, New South Wales, Australia.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook